Bg pattern

AMCHAFIBRIN 500 mg FILM-COATED TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use AMCHAFIBRIN 500 mg FILM-COATED TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Amchafibrin 500 mg Film-Coated Tablets

tranexamic acid

Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.

  • Keep this package leaflet, as you may need to read it again. If you have any questions, consult your doctor or pharmacist.
  • This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
    • If you experience side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. See section 4.

Contents of the Package Leaflet

  1. What Amchafibrin is and what it is used for
  2. What you need to know before taking Amchafibrin
  3. How to take Amchafibrin
  4. Possible side effects

5 Conservation of Amchafibrin

  1. Contents of the pack and further information

1. What Amchafibrin is and what it is used for

Amchafibrin contains the active ingredient tranexamic acid, which belongs to a group of medications called antifibrinolytics.

This medication is indicated for the treatment and prevention of excessive bleeding associated with abnormal bleeding, such as:

  • any type of prostate or bladder surgery,
  • abnormally heavy and prolonged menstrual bleeding,
  • patients with a tendency to bleed abnormally (hemophiliacs) who undergo dental surgery (extractions),
  • localized swelling that affects the mouth and upper respiratory tract (hereditary angioedema).
Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before taking Amchafibrin

Do not take Amchafibrin:

  • If you are allergic to the active ingredient or any of the other components of this medication (listed in section 6).
  • If you have a tendency to form blood clots (thrombi).
  • If you are at risk of excessive bleeding due to a coagulation disorder called consumption coagulopathy.
  • If you have severe kidney problems (severe renal insufficiency).
  • If you have a history of seizures.

In case of doubt, consult your doctor or pharmacist.

Warnings and precautions

Consult your doctor or pharmacist before starting to take Amchafibrin:

  • If you have impaired renal function.
  • If you have hematuria (blood in the urine) of renal origin, as a clot may form in the urethra that prevents urine from coming out.
  • If you are taking oral contraceptives, due to the increased risk of thrombosis.

Other medications and Amchafibrin

Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.

It is important to inform your doctor if you are taking any of the following medications:

  • Fibrinolytic medications (used to help break down blood clots). This is because tranexamic acid would cancel the effect of these medications.
  • Oral contraceptives.

In case of doubt, consult your doctor or pharmacist.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

Tranexamic acid is excreted in breast milk, although in minimal amounts. If you are breastfeeding, consult your doctor or pharmacist before taking this medication.

Children

The primary use of tranexamic acid in children is for dental extraction. Use with caution. The dose of this medication in children and adolescents should be calculated based on body weight.

Driving and using machines

No studies have been conducted on the effects on the ability to drive and use machines. In case of dizziness or drowsiness, it is not recommended to drive vehicles or operate machinery.

3. How to take Amchafibrin

Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

Adults:

Usual dose

Take 2 to 3 tablets, 2-3 times a day.

The exact dose for you depends on the reason why this medication has been prescribed to you. Follow your doctor's instructions regarding how many tablets to take, when to take them, and the duration of treatment.

Dose in certain specific cases:

  • Total or partial prostate removal (prostatectomy): during the first 3 days after surgery, take 2 tablets, 3 to 4 times a day, until there is no blood in the urine.
  • Abnormally heavy and prolonged menstrual bleeding (metrorrhagia): take 2 tablets, 3 times a day, for 3 or 4 days. Do not exceed a total dose of 4 g per day (8 tablets). Treatment with Amchafibrin should not be started until menstrual bleeding has begun.

Use in advanced age

No dose reduction is necessary unless there is renal insufficiency.

Renal insufficiency

This medication may accumulate in patients with renal insufficiency, so the dose should be reduced in these cases.

Use in children and adolescents

Your doctor will indicate the exact dose to be given to the child. Your doctor will calculate the dose based on the child's weight.

In case of doubt, ask your doctor or pharmacist.

If you take more Amchafibrin than you should

If you take more Amchafibrin than you should, you may experience nausea, vomiting, orthostatic symptoms, and/or hypotension. In this case, vomiting should be induced, gastric lavage should be performed, and treatment with activated charcoal should be started. Maintain high fluid intake to favor renal elimination.

In case of overdose, consult your doctor or pharmacist immediately, or call the Toxicology Information Service. Tel. 91 562 04 20. Bring this package leaflet with you.

If you forget to take Amchafibrin

Do not take a double dose to make up for forgotten doses, but continue taking this medication as usual.

If you interrupt treatment with Amchafibrin

Do not interrupt treatment with this medication without consulting your doctor.

If you have any further questions about the use of this medication, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone experiences them.

Immediately inform your doctor of any of the following situations:

  • If you experience a rash or allergic reaction such as itching, swelling of the lips/tongue, or wheezing/difficulty breathing. In such cases, stop taking the tablets immediately and inform your doctor as soon as possible.
  • If you experience blood clots in the veins (a rare side effect that may affect up to 1 in 1,000 people), especially in the legs (symptoms are swelling, pain, and redness in the legs), which can move through the blood vessels to the lungs and cause chest pain and difficulty breathing. If you experience any of these symptoms, seek medical attention immediately.

Rare (affect 1 to 10 patients in every 1,000)

  • Visual disturbances, especially in color vision.
  • Formation of a blood clot in an eye. This can cause bleeding in the eye or vision loss.
  • Itching, redness, or swelling of the skin.

Very rare (affect less than 1 patient in every 10,000)

  • Formation of a blood clot in the blood vessels (i.e., thrombosis).
  • Allergic reactions that can cause difficulty breathing or dizziness.
  • Nausea.
  • Vomiting.
  • Diarrhea.
  • Seizures or convulsions.
  • General feeling of discomfort (malaise) and low blood pressure (hypotension), with or without loss of consciousness.

Nausea, vomiting, and diarrhea are usually mild and disappear quickly; however, if they persist, inform your doctor or pharmacist.

Reporting side effects

If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.

5. Conservation of Amchafibrin

Keep this medication out of the sight and reach of children.

Do not store above 30°C.

Do not use this medication after the expiration date shown on the packaging after "CAD" or "EXP". The expiration date is the last day of the month indicated.

Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.

6. Contents of the pack and further information

Composition of Amchafibrin

  • The active ingredient is tranexamic acid. Each film-coated tablet contains 500 mg of tranexamic acid.
  • The other components are: microcrystalline cellulose, low-substituted hydroxypropylcellulose, talc, magnesium stearate, povidone, anhydrous colloidal silica, butyl methacrylate basic copolymer, titanium dioxide (E 171), macrogol, and vanillin.

Appearance of the product and contents of the pack

White, oval, film-coated tablets with a score on one side.

The tablets are presented in PVC/PVDC-Aluminum blisters, and the available pack size is 30 tablets.

Marketing authorization holder and manufacturer

Marketing authorization holder

Viatris Healthcare Limited

Damastown Industrial Park

Mulhuddart, Dublin 15

Dublin

Ireland

Manufacturer

Madaus GmbH

Lütticher Str. 5

53842 Troisdorf,

Germany

You can request more information about this medication from the local representative of the marketing authorization holder:

Viatris Pharmaceuticals, S.L.

C/General Aranaz, 86

28027 Madrid

Spain

Date of the last revision of this package leaflet:November 2022

Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/

Online doctors for AMCHAFIBRIN 500 mg FILM-COATED TABLETS

Discuss questions about AMCHAFIBRIN 500 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for AMCHAFIBRIN 500 mg FILM-COATED TABLETS?
AMCHAFIBRIN 500 mg FILM-COATED TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in AMCHAFIBRIN 500 mg FILM-COATED TABLETS?
The active ingredient in AMCHAFIBRIN 500 mg FILM-COATED TABLETS is tranexamic acid. This information helps identify medicines with the same composition but different brand names.
How much does AMCHAFIBRIN 500 mg FILM-COATED TABLETS cost in pharmacies?
The average pharmacy price for AMCHAFIBRIN 500 mg FILM-COATED TABLETS is around 4.62 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures AMCHAFIBRIN 500 mg FILM-COATED TABLETS?
AMCHAFIBRIN 500 mg FILM-COATED TABLETS is manufactured by Viatris Healthcare Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of AMCHAFIBRIN 500 mg FILM-COATED TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether AMCHAFIBRIN 500 mg FILM-COATED TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to AMCHAFIBRIN 500 mg FILM-COATED TABLETS?
Other medicines with the same active substance (tranexamic acid) include TRANEXAMIC ACID APC INSTYTUT 500 mg FILM-COATED TABLETS, TRANEXAMIC ACID BAXTER 100 mg/mL INJECTABLE SOLUTION, TRANEXAMIC ACID ZENTIVA 500 mg FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media